Editorial Commentary
Re-evaluating antiplatelet therapy post-coronary artery bypass grafting: insights from the DACAB trial’s five-year follow-up
AME Clinical Trials Review
2025;
3:
6
.
(25 February 2025)
Editorial Commentary
Innovative dual approach: CD40 agonist and mFOLFIRINOX combination therapy in metastatic pancreatic cancer
AME Clinical Trials Review
2025;
3:
5
.
(25 February 2025)
Editorial Commentary
DACAB trial supports long-term use of ticagrelor and aspirin dual therapy after coronary artery bypass grafting
AME Clinical Trials Review
2025;
3:
4
.
(25 February 2025)
Editorial Commentary
Is EndoRotor the answer to residual colonic lesions?
AME Clinical Trials Review
2025;
3:
3
.
(25 February 2025)
Editorial Commentary
Should we target demethylation in acute myeloid leukemia?
AME Clinical Trials Review
2025;
3:
2
.
(25 February 2025)
Editorial Commentary
Upfront axillary surgical management—a commentary on previously underrepresented patient groups and how the SENOMAC trial righted this wrong
AME Clinical Trials Review
2025;
3:
1
.
(25 February 2025)
Review Article
Cleaning the scope: have randomized clinical trials clarified the benefits of minimally invasive thoracic surgery for non-small cell lung cancer?—a narrative review
AME Clinical Trials Review
2024;
2:
112
.
(25 December 2024)
Editorial Commentary
Less radiation, same bang, fewer bucks?
AME Clinical Trials Review
2024;
2:
111
.
(25 December 2024)
Editorial Commentary
Neoadjuvant FOLFIRINOX in resectable pancreatic cancer: impact of the NORPACT-1 trial
AME Clinical Trials Review
2024;
2:
110
.
(25 December 2024)
Editorial Commentary
Need of the hour—advancements in treatment of pancreatic cancer
AME Clinical Trials Review
2024;
2:
109
.
(25 December 2024)
Editorial Commentary
Combining [177Lu]Lu-PSMA-617 and enzalutamide in metastatic castration-resistant prostate cancer: promising but with caveats for now
AME Clinical Trials Review
2024;
2:
108
.
(25 December 2024)
Editorial Commentary
Tislelizumab in hepatocellular carcinoma: a duet or a solo performance?
AME Clinical Trials Review
2024;
2:
107
.
(25 December 2024)
Editorial Commentary
To fast or not to fast—that is the question?
AME Clinical Trials Review
2024;
2:
106
.
(25 December 2024)
Editorial Commentary
The COMBAT trial: use of bipolar androgen therapy to enhance immune checkpoint blockade in the management of metastatic castration-resistant prostate cancer
AME Clinical Trials Review
2024;
2:
105
.
(25 December 2024)
Editorial Commentary
Novel agents in acute lymphoblastic leukemia: an expanding role for inotuzumab ozogamicin in patients with measurable residual disease
AME Clinical Trials Review
2024;
2:
104
.
(25 December 2024)
Editorial Commentary
Optimizing antiplatelet therapy after coronary artery bypass graft: selection, dosing, and duration
AME Clinical Trials Review
2024;
2:
103
.
(25 December 2024)
Editorial Commentary
Comparison of drug-eluting bead transcatheter arterial chemoembolization (TACE) versus conventional TACE for hepatocellular carcinoma with portal vein thrombus
AME Clinical Trials Review
2024;
2:
102
.
(25 December 2024)
Editorial Commentary
FLAURA in the real world: osimertinib in potentially trial-eligible and ineligible patients with EGFR-mutated advanced non-small cell lung cancer
AME Clinical Trials Review
2024;
2:
101
.
(25 December 2024)
Editorial Commentary
Antiplatelet therapy after coronary artery bypass surgery: the results from the randomized DACAB trial
AME Clinical Trials Review
2024;
2:
100
.
(25 December 2024)
Editorial Commentary
What is the optimal therapeutic option for patients diagnosed with hormone receptor-positive, HER2-negative breast cancer in visceral crisis?—insights from the RIGHT CHOICE trial
AME Clinical Trials Review
2024;
2:
99
.
(25 December 2024)
Editorial Commentary
Ficonalkib: a new contender in ALK-positive non-small cell lung cancer treatment
AME Clinical Trials Review
2024;
2:
98
.
(25 December 2024)
Editorial Commentary
The significance of local intervention for oligometastatic esophageal squamous cell carcinoma
AME Clinical Trials Review
2024;
2:
97
.
(25 December 2024)
Editorial Commentary
From lifelong therapy to intermittent treatment: the future of chronic myeloid leukemia management—commentary on interim results from DAstop2 trial
AME Clinical Trials Review
2024;
2:
96
.
(25 December 2024)
Editorial Commentary
Drug-coated ballons finally land in the United States: an appraisal of the agent IDE randomized clinical trial
AME Clinical Trials Review
2024;
2:
95
.
(25 December 2024)
Editorial Commentary
Review on LAURA: is it a game changer for unresectable stage III EGFR-mutated non-small-cell lung cancer?
AME Clinical Trials Review
2024;
2:
94
.
(25 December 2024)
Editorial Commentary
Can PET-CT improve the staging and outcome of patients with muscle-invasive bladder cancer?
AME Clinical Trials Review
2024;
2:
93
.
(25 December 2024)
Editorial Commentary
Can robot-assisted oesophagectomy really improve outcomes?
AME Clinical Trials Review
2024;
2:
92
.
(25 December 2024)
Letter to the Editor
Are metastatic central lymph nodes (D3 volume) in right-sided colon cancer “REALLY” a sign of systemic disease?—a sub-group analysis of an ongoing multicenter trial
AME Clinical Trials Review
2024;
2:
91
.
(25 October 2024)
Editorial Commentary
One more point for ibrutinib plus rituximab over fludarabine, cyclophosphamide and rituximab (FCR)
AME Clinical Trials Review
2024;
2:
90
.
(25 October 2024)
Editorial Commentary
The optimum balance between efficacy and toxicity with different doses of trastuzumab deruxtecan in HER2 mutated non-small cell lung cancer in DESTINY-Lung02 trial
AME Clinical Trials Review
2024;
2:
89
.
(25 October 2024)